Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MESD (Mesoderm development LDL receptor chaperone) is a specialized endoplasmic reticulum chaperone that is essential for folding and maturation of low-density lipoprotein receptor (LDLR) family members, particularly the canonical Wnt co-receptors LRP5 and LRP6[1][2][3]. MESD ensures proper formation of the β-propeller/EGF modules in these proteins, enabling their export to the plasma membrane. MESD is critical for embryonic development, as it is essential for mesoderm induction, embryonic polarity, and for postnatal functions including bone formation and neuromuscular junction development[1][3]. The protein contains distinct chaperone and escort domains, allowing it to both template correct receptor folding and escort properly assembled complexes out of the ER[2]. Loss of MESD function causes severe developmental and metabolic defects due to misfolding and ER retention of target LDL receptors, particularly affecting the Wnt/β-catenin signaling axis[1][2][3][4]. No drugs are currently known to target MESD directly. The gene is associated with rare forms of osteogenesis imperfecta and possibly other developmentally-linked diseases[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mesoderm development LDL receptor chaperone (MESD).